Canakinumab is in clinical development for the treatment of adults with Schnitzler syndrome. Schnitzler syndrome is a rare inflammatory condition. The exact underlying cause is currently unknown, however certain proteins of the immune system (including cytokines) play a role in the development of the inflammation in Schnitzler syndrome. The first clinical sign of this condition is usually a mildly or non-itchy skin rash; other symptoms include fevers, joint pain and inflammation, enlarged internal organs, bone pain and muscle aches. There are currently no approved treatments for Schnitzler syndrome.
Canakinumab for Schnitzler syndrome
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Partners-Industry_Motifs_Motifs_Conduction-broadcasting_RGB-scaled_edited_1233.jpg)
Canakinumab is in clinical development for the treatment of adults with Schnitzler syndrome. Schnitzler syndrome is a rare inflammatory condition. The exact underlying cause is currently unknown, however certain proteins of the immune system (including cytokines) play a role in the development of the inflammation in Schnitzler syndrome.
Interventions:
Canakinumab (Ilaris; ACZ885)
Indications:
Schnitzler syndrome
Therapeutic Areas:
Immunology
Year:
2021